These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9792159)

  • 1. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.
    Tempfer C; Hefler L; Heinzl H; Loesch A; Gitsch G; Rumpold H; Kainz C
    Br J Cancer; 1998 Oct; 78(8):1108-12. PubMed ID: 9792159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M3/M21 serum levels in women with adnexal masses and inflammatory diseases.
    Hefler L; Tempfer C; Heinzl H; Haeusler G; Steindl P; Schneeberger C; Gitsch G; Kainz C
    Int J Cancer; 1998 Aug; 79(4):434-8. PubMed ID: 9699539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
    Int J Gynecol Cancer; 2001; 11(4):277-82. PubMed ID: 11520365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYFRA 21-1 and Placental Growth Factor as Screening Markers for Endometriosis.
    Cho HY; Kyung MS
    Med Sci Monit; 2019 Feb; 25():1087-1092. PubMed ID: 30737365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer.
    Niklinski J; Burzykowski T; Niklinska W; Laudanski J; Chyczewski L; Rapellino M; Furman M
    Eur Respir J; 1998 Dec; 12(6):1424-8. PubMed ID: 9877503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Reiser E; Aust S; Seebacher V; Reinthaller A; Helmy-Bader S; Schwameis R; Grimm C; Polterauer S
    Gynecol Oncol; 2017 Dec; 147(3):690-694. PubMed ID: 28935270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
    Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
    Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer.
    Wu HH; Wang PH; Yeh JY; Chen YJ; Yen MS; Huang RL; Tsai YJ; Yuan CC
    Taiwan J Obstet Gynecol; 2014 Mar; 53(1):30-4. PubMed ID: 24767643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Management of Adnexal Masses.
    Biggs WS; Marks ST
    Am Fam Physician; 2016 Apr; 93(8):676-81. PubMed ID: 27175840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations.
    Callet N; Cohen-Solal Le Nir CC; Berthelot E; Pichon MF
    Eur J Gynaecol Oncol; 1998; 19(1):50-6. PubMed ID: 9476060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
    Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
    Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyfra 21-1, a new marker of lung cancer.
    Grenier J; Pujol JL; Guilleux F; Daures JP; Pujol H; Michel FB
    Nucl Med Biol; 1994 Apr; 21(3):471-6. PubMed ID: 9296767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.
    Uenishi T; Kubo S; Hirohashi K; Tanaka H; Shuto T; Yamamoto T; Nishiguchi S
    Br J Cancer; 2003 Jun; 88(12):1894-9. PubMed ID: 12799633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyfra 21-1 as a marker of lung cancer.
    Kinoshita M; Watanabe H; Ichiki M; Sumita S; Okubo Y; Matsunami M; Furuno H; Shiraishi T; Rikimaru T; Oizumi K
    Kurume Med J; 1998; 45(1):7-9. PubMed ID: 9658744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
    Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
    Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
    Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N
    Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.